Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Point-of-care testing: physician's office and other alternative site testing

This article was originally published in Clinica

Executive Summary

The market for physician's office laboratory (POL) testing covers a wide range of product segments, including chemistry, immunochemistry, haematology, infectious disease, urinalysis, allergy and diabetes. The market is mature, since the number of labs worldwide is not growing rapidly and patient load is also relatively stable. The customer base ranges from small labs that primarily perform simple tests which do not require the skills of a laboratory technician (CLIA-waived tests or provider-performed microscopy procedures in the US), to large operations serving group practices that are equivalent to some hospital-based labs in terms of equipment and test volume. Market data is most extensive in the US, which accounts for the majority of POLs as well as most of the POL products marketed worldwide.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT096028

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel